Kylie Keijzer

8PUBLICATIONS
31CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursHaematologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 15, 2026
Risk of thrombosis and bleeding following CAR T-cell therapy: Insights from the Dutch "Follow that CAR!" registry.

|Feb 10, 2026
Author Correction: Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.

Janneke W de Boer, Kylie Keijzer, Jaap A van Doesum

|Nov 25, 2025
Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.

Janneke W de Boer, Kylie Keijzer, Jaap A van Doesum

|Sep 19, 2025
Beneficial effect of PTCy and a short duration of immune suppression on relapse risk in acute myeloid leukemia patients with pretransplant MRD.

L M Morsink, K Keijzer, C L E Hazenberg

|Jul 16, 2025
Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections, and survival after CART in R/R LBCL.

Janneke W de Boer, Kylie Keijzer, Suzanne van Dorp

|Jun 20, 2025
Serum TARC: a biomarker for early detection or exclusion of relapse in classic Hodgkin lymphoma.

Sophie A Teesink, Lydia Visser, Marcel Nijland

Pageof 2

Frequent Collaborators

6 joint publications

Janneke W de Boer

5 joint publications

Tom van Meerten

3 joint publications

Joost Sp Vermaat

3 joint publications

Anne G H Niezink